Role Of Progesterone Receptor Expression Research Articles

The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.

Fifteen percent of patients with endometrial cancer (EC) have advanced stage disease or develop a recurrence. Progestins have been applied as systemic treatment for decades, but there is limited evidence on response prediction with biomarkers and toxicity. To review the response and toxicity of progestin therapy and stratify response to progesterone receptor (PR) expression and tumour grade. We used the search terms 'Endometrial cancer', 'Progestins', 'Disease progression', 'Recurrence' and related terms in Pubmed, Embase and Cochrane databases. Studies on patients with advanced stage or recurrent EC treated with progestin monotherapy were included. Studies on adjuvant therapy, with fewer than ten cases and with sarcoma histology were excluded. Evaluation for bias was performed with the Revised Cochrane RoB2 tool for randomised studies and the ROBINS-I tool for non-randomised studies. A random effects meta-analysis was performed with the overall response rate (ORR), clinical benefit rate and toxicity as primary outcome measures. Twenty-six studies (1639 patients) were included. The ORR of progestin therapy was 30% (95% CI 25-36), the clinical benefit rate was 52% (95% CI 42-61). In PR-positive EC, the ORR was 55%, compared with 12% in PR-negative disease (risk difference 43%, 95% CI 15-71). Severe toxicity occurred in 6.5%. Progestin therapy is a viable treatment option in patients with advanced stage and recurrent EC with low toxicity and high ORR in PR-positive disease. The role of PR expression in relation to progression-free survival and overall survival is unclear.

Prognostic role of progesterone receptor expression in a population-based analysis.

The role of progesterone (PR) expression in the management of breast cancer is controversial. The aim of this study is to evaluate the characteristics and prognosis of progesterone status among breast cancers patients in a population-based analysis. Through the Tuscan Cancer Registry data on all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Histological reports were re-examined to obtain information on the percentage of positive tumor cells for estrogen (ER), progesterone (PR) receptors, Ki67 marker and human epidermal growth factor 2 (HER2). Information on age, stage, differentiation grade were also obtained. Out of 1487 patients, 28% had PR-breast cancer. These patients were older (p 0.006) than PR+cancer patients, with more frequently high Ki67 (p<0.0001), HER2+(p<0.0001), ER- (p<0.0001) tumoral expression. The ER+/PR+subtype was the most represented (n.1053), while ER-/PR+was the most rare (n.23); 210 cases (14.1%) ER+PR- and 201 (13.5%) ER-/PR- cases were found. Analysis of survival by the Cox proportional hazards model showed an independent prognostic value of PR expression (p<0.0001), also when estrogen, Ki67, HER2 status and age were included. The 5-year cancer-specific survival was 82.1, 86.5, 100, 92% for ER-/PR-, ER+/PR-, ER-/PR+, ER+/PR+subtype, respectively. Our study revealed significant differences in clinicopathological characteristics among breast cancer according to PR expression and confirmed its prognostic independent role, suggesting a role of PR in the improvement of breast cancer prognostic characterization.

The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival

PurposeProgesterone has been shown to impact the development of hormone-sensitive cancers, such as breast and ovarian cancers. Emerging evidence has revealed a possible role of progesterone in the tumorigenesis of other cancers, including lung cancer. Herein, we aimed to elucidate the prevalence and prognostic significance of progesterone receptor (PR) expression in non-small cell lung cancer (NSCLC) tissue. ExperimentalTumor tissue samples were collected from our patient cohort consisting of 335 NSCLC patients with stage I–IIIA disease. Tissue microarrays (TMAs) were constructed, and immunohistochemical (IHC) analyses were performed to evaluate the PR expression in the tumor epithelial and stromal compartments. ResultsIn a univariate analysis, positive PR expression in the stromal tumor compartment (P=0.005) was significantly and independently associated with a favorable outcome for both genders. Furthermore, positive PR expression in tumor epithelial cells (P=0.003) correlated with a poor prognosis for female patients. In a multivariate analysis, positive PR expression in the tumor stroma (P=0.007) was an independent prognostic factor for improved disease-specific survival (DSS). Positive PR expression in tumor epithelial cells emerged as an independent prognostic factor in female patients (P=0.001) for poor DSS. ConclusionsWe show that PR expression in tumor-surrounding stromal cells is associated with improved DSS for both male and female patients. Additionally, we reveal that positive PR expression in tumor epithelial cells is an independent, unfavorable prognosticator for DSS in female patients, making PR expression a potential marker for prognostic stratification in NSCLC.

Role of progesterone receptor expression and proliferative activity in predicting the recurrence of meningioma

Introduction A putative role for progesterone in the growth of meningioma has been suggested. The aim of this study was to attest the role of progesterone receptor (PR) in predicting the biological behavior of meningioma. Material and methods The study included 30 cases of meningioma, 15 (50%) recurrent and 15 (50%) non-recurrent. The immunohistochemical expression of PR was studied. Cell kinetic using the Ki67/MIB-1 labelling index (LI) was evaluated and correlated to PR expression. Results PR expression was significantly more common in benign meningioma (BM) than atypical meningioma (AM) and malignant meningioma (MM). The mean Ki-67/MIB-1 LI was significantly highest in MM, high in AM and lowest in BM. In PR-negative meningioma, the mean Ki-67/MIB-1 LI was significantly higher compared with PR-positive meningioma. In the recurrent group, PR was frequently immunonegative and the mean Ki-67/MIB-1 LI was higher than that in the non-recurrent group. The difference in PR expression between non-recurrent and recurrent cases was significant only in BM. The difference in Ki-67/ MIB-1 LI was significant only when recurrent meningioma was compared with non-recurrent tumor, irrespective of the grade. Conclusion BM expresses PR more than AM and MM. The absence of this expression in BM implies a likely risk for recurrence. Ki-67/MIB-1 LI is valuable to predict tumor grade and the overall risk of recurrence. However, it must be interpreted with caution in BM.

Role of progesterone receptor expression and proliferative activity in predicting the recurrence of meningioma

Introduction A putative role for progesterone in the growth of meningioma has been suggested. The aim of this study was to attest the role of progesterone receptor (PR) in predicting the biological behavior of meningioma. Material and methods The study included 30 cases of meningioma, 15 (50%) recurrent and 15 (50%) non-recurrent. The immunohistochemical expression of PR was studied. Cell kinetic using the Ki67/MIB-1 labelling index (LI) was evaluated and correlated to PR expression. Results PR expression was significantly more common in benign meningioma (BM) than atypical meningioma (AM) and malignant meningioma (MM). The mean Ki-67/MIB-1 LI was significantly highest in MM, high in AM and lowest in BM. In PR-negative meningioma, the mean Ki-67/MIB-1 LI was significantly higher compared with PR-positive meningioma. In the recurrent group, PR was frequently immunonegative and the mean Ki-67/MIB-1 LI was higher than that in the non-recurrent group. The difference in PR expression between non-recurrent and recurrent cases was significant only in BM. The difference in Ki-67/ MIB-1 LI was significant only when recurrent meningioma was compared with non-recurrent tumor, irrespective of the grade. Conclusion BM expresses PR more than AM and MM. The absence of this expression in BM implies a likely risk for recurrence. Ki-67/MIB-1 LI is valuable to predict tumor grade and the overall risk of recurrence. However, it must be interpreted with caution in BM.